-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Pre-existing -X- _ O
immunity -X- _ O
to -X- _ O
Vaccinia -X- _ O
Tian -X- _ O
Tan -X- _ O
virus -X- _ O
( -X- _ O
VTT -X- _ O
) -X- _ O
resulting -X- _ O
from -X- _ O
a -X- _ O
large -X- _ O
vaccination -X- _ O
campaign -X- _ O
against -X- _ O
smallpox -X- _ O
prior -X- _ O
to -X- _ O
the -X- _ O
early -X- _ O
1980s -X- _ O
in -X- _ O
China -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
a -X- _ O
major -X- _ O
issue -X- _ O
for -X- _ O
application -X- _ O
of -X- _ O
VTT-vector -X- _ O
based -X- _ O
vaccines. -X- _ O
It -X- _ O
is -X- _ O
essential -X- _ O
to -X- _ O
establish -X- _ O
a -X- _ O
sensitive -X- _ O
and -X- _ O
high- -X- _ O
throughput -X- _ O
neutralization -X- _ O
assay -X- _ O
to -X- _ O
understand -X- _ O
the -X- _ O
epidemiology -X- _ O
of -X- _ O
Vaccinia-specific -X- _ B-Patient
immunity -X- _ I-Patient
in -X- _ I-Patient
current -X- _ I-Patient
populations -X- _ I-Patient
in -X- _ I-Patient
China. -X- _ I-Patient
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
A -X- _ O
new -X- _ O
anti-Vaccinia -X- _ O
virus -X- _ O
( -X- _ O
VACV -X- _ O
) -X- _ O
neutralization -X- _ O
assay -X- _ O
that -X- _ O
used -X- _ O
the -X- _ O
attenuated -X- _ O
replication-competent -X- _ O
VTT -X- _ O
carrying -X- _ O
the -X- _ O
firefly -X- _ O
luciferase -X- _ O
gene -X- _ O
of -X- _ O
Photinus -X- _ O
pyralis -X- _ O
( -X- _ O
rTV-Fluc -X- _ O
) -X- _ O
was -X- _ O
established -X- _ O
and -X- _ O
standardized -X- _ O
for -X- _ O
critical -X- _ O
parameters -X- _ O
that -X- _ O
included -X- _ O
the -X- _ O
choice -X- _ O
of -X- _ O
cell -X- _ O
line -X- _ O
, -X- _ O
viral -X- _ O
infection -X- _ O
dose -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
infection -X- _ O
time. -X- _ O
The -X- _ O
current -X- _ O
study -X- _ O
evaluated -X- _ O
the -X- _ O
maintenance -X- _ O
of -X- _ O
virus-specific -X- _ O
immunity -X- _ O
after -X- _ O
smallpox -X- _ O
vaccination -X- _ O
by -X- _ O
conducting -X- _ O
a -X- _ O
non-randomized -X- _ O
, -X- _ O
cross-sectional -X- _ O
analysis -X- _ O
of -X- _ O
antiviral -X- _ B-Patient
antibody-mediated -X- _ I-Patient
immune -X- _ I-Patient
responses -X- _ I-Patient
in -X- _ I-Patient
volunteers -X- _ I-Patient
examined -X- _ I-Patient
30â€“55 -X- _ I-Patient
years -X- _ I-Patient
after -X- _ I-Patient
vaccination. -X- _ I-Patient
The -X- _ B-Outcome
rTV-Fluc -X- _ I-Outcome
neutralization -X- _ I-Outcome
assay -X- _ I-Outcome
was -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
detect -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
( -X- _ I-Outcome
NAbs -X- _ I-Outcome
) -X- _ I-Outcome
against -X- _ I-Outcome
Vaccinia -X- _ I-Outcome
virus -X- _ I-Outcome
without -X- _ I-Outcome
the -X- _ I-Outcome
ability -X- _ I-Outcome
to -X- _ I-Outcome
differentiate -X- _ I-Outcome
strains -X- _ I-Outcome
of -X- _ I-Outcome
Vaccinia -X- _ I-Outcome
virus. -X- _ I-Outcome
We -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
neutralizing -X- _ I-Outcome
titers -X- _ I-Outcome
measured -X- _ I-Outcome
by -X- _ I-Outcome
our -X- _ I-Outcome
assay -X- _ I-Outcome
were -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
obtained -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
traditional -X- _ I-Outcome
plaque -X- _ I-Outcome
reduction -X- _ I-Outcome
neutralization -X- _ I-Outcome
test -X- _ I-Outcome
( -X- _ I-Outcome
PRNT -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Using -X- _ O
this -X- _ O
assay -X- _ O
, -X- _ O
we -X- _ O
found -X- _ O
a -X- _ O
low -X- _ B-Outcome
prevalence -X- _ I-Outcome
of -X- _ I-Outcome
NAb -X- _ I-Outcome
to -X- _ I-Outcome
VTT -X- _ I-Outcome
( -X- _ I-Outcome
7.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
individuals -X- _ I-Outcome
born -X- _ I-Outcome
before -X- _ I-Outcome
1980 -X- _ I-Outcome
from -X- _ I-Outcome
Beijing -X- _ I-Outcome
and -X- _ I-Outcome
Anhui -X- _ I-Outcome
provinces -X- _ I-Outcome
in -X- _ I-Outcome
China -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
when -X- _ I-Outcome
present -X- _ I-Outcome
, -X- _ I-Outcome
anti-VTT -X- _ I-Outcome
NAb -X- _ I-Outcome
titers -X- _ I-Outcome
were -X- _ I-Outcome
low. -X- _ I-Outcome
No -X- _ I-Outcome
NAbs -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
all -X- _ I-Outcome
222 -X- _ I-Outcome
samples -X- _ I-Outcome
from -X- _ I-Outcome
individuals -X- _ I-Outcome
born -X- _ I-Outcome
after -X- _ I-Outcome
1980. -X- _ I-Outcome
There -X- _ O
was -X- _ O
no -X- _ B-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
observed -X- _ O
for -X- _ O
titer -X- _ O
or -X- _ O
prevalence -X- _ O
by -X- _ O
gender -X- _ O
, -X- _ O
age -X- _ O
range -X- _ O
and -X- _ O
geographic -X- _ O
origin. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
A -X- _ O
simplified -X- _ O
, -X- _ O
sensitive -X- _ O
, -X- _ O
standardized -X- _ O
, -X- _ O
reproducible -X- _ O
, -X- _ O
and -X- _ O
high-throughput -X- _ O
assay -X- _ O
was -X- _ O
developed -X- _ O
for -X- _ O
the -X- _ O
quantitation -X- _ B-Intervention
of -X- _ I-Intervention
NAbs -X- _ I-Intervention
against -X- _ I-Intervention
different -X- _ I-Intervention
Vaccinia -X- _ I-Intervention
strains. -X- _ I-Intervention
The -X- _ O
current -X- _ O
study -X- _ O
provides -X- _ O
useful -X- _ O
insights -X- _ O
for -X- _ O
the -X- _ O
future -X- _ O
development -X- _ O
of -X- _ O
VTT-based -X- _ O
vaccination -X- _ O
in -X- _ O
Beijing -X- _ O
and -X- _ O
Anhui -X- _ O
provinces -X- _ O
of -X- _ O
China -X- _ O
. -X- _ O

